Given the observed requirement for decrease in both pERK and pAKT downstream of mutant NRAS and the intense efforts to develop inhibitors targeting BRAF, MEK1/2 and PI3K in progress, we sought to understand if combined knock-down of RAF or MEK with PI3K would be an effective strategy for treatment of NRAS mutant melanomas. This evidence concerns the gene BRAF and melanoma.